Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

NEW IDEA ON ETP

This post was just published on ZYX BuyChange Alert ETP  is a natural gas MLP and has a dividend of 8.1%.  Those who have been interested in a high dividend paid MLP there is an opportunity, the stock has dipped below the secondary price. The buy zone is $41 to $43.82, target zone is $50 to $55. No stops at this time. Please be sure to follow Trade Management Guidelines.

Read More »

ARENA OBESITY DRUG APPROVAL MAY SIGNAL FDA OPENING UP FAT PILL FLOODGATES

The U.S. Food and Drug Administration (FDA) has approved the first obesity drug in 15 years. The drug is lorcaserin, dubbed Belviq, from Arena Pharmaceuticals (ARNA). The drug works by affecting the area of the brain that regulates metabolism. The issue with weight loss drugs has not been efficacy, rather the side effects.  The drug from Arena works similarly to Fen-phen.  Fen-phen was banned about 15 years ago in the aftermath of serious side effects related to heart valves. The drug will be marketed by a Japanese company,Eisai.  Projections are that lorcaserin will become a $1.5 billion drug. Jack Lief,

Read More »

NEW IDEA ON OREXIGEN THERAPUTICS (OREX)

This post was  published earlier on ZYX BuyChange Alert OREX is a sympathy play with ARNA. FDA has just approved ARNA weight loss drug. The risk is very high and this trade is only for aggressive investors. Buy zone is $3.90 -4.61. Stop zone is 3.43-3.73. Target zone is $6-7.50. This is a highly speculative position, please be sure to follow the Trade Management Guidelines. Only aggressive investors may chase the stock higher than the top band of the buy zone.

Read More »

WHY FACEBOOK FORCING ITS EMAIL ON YOU IS BRILLIANT

Facebook (FB) took a brilliant step in the right direction by making the visible email on a person’s profile @facebook.com by default. Long ago I learned that change has unintended consequences.  The unintended consequence of the change that Facebook has made is that media has blown up with extreme negative reaction. Some outrage is understandable because Facebook made the change without user’s consent. In my view the change is brilliant because it is good for the users, the marketers, and Facebook.  I write about investments, this change is good for potential Facebook investors. There have been a lot of privacy

Read More »

APPLE BETTER OFF WITH LICENSING THAN PATENT WARS

Apple has been pursuing a scorched earth litigation strategy using its patent portfolio againstGoogle and its Android mobile operating system.  Shareholders and gurus almost universally support this strategy. Either there are not many who see Apple’s strategy as flawed or those who see the strategy as flawed are hiding under a rock.  I do not blame anyone for not voicing an unpopular opinion.  Who needs the hate mail? I distinctly remember the amount of hate mail I received after I wrote an open letter to Tim Cook on December 29, 2011, pointing out the flaws in Apple’s strategy and suggesting an alternative

Read More »

JUDGE TOSSES APPLE’S CASE AGAINST MOTOROLA, APPLE MANAGEMENT MESSES UP

Apple and Motorola have been vigorously fighting patent lawsuits with each other.  Motorola Mobilityis simply a proxy for Google because it is now owned by Google. A federal judge in Chicago has formally dismissed a patent case brought by Apple against Motorola with prejudice.  ‘With prejudice’ means that neither side can refile the case, however they can appeal the judge’s decision. In my opinion, this is a big loss for Apple in the long run as it will allow Google to compete more effectively against Apple. Apple has a reputation for doing everything very well.  The irony here is that Apple doomed its case by its own

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content